In 2020, FGFR-targeting erdafitinib and pemigatinib were approved by the Food and Drug Administration for use in FGFR3-mutated urothelial carcinomas and FGFR2-fusion cholangiocarcinomas [13]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.